Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34575629/
Cannabinoid receptors (CBR) are potential therapeutic targets for breast cancer. However, the role of CBR in breast cancer survival remains poorly understood. Data from a prospective cohort of 522 women...
-
Breast Cancer Connect4yrKey Points • Source: Journal of Personalized Medicine • Conclusion/Relevance: “This is the first study to evaluate both CBR1 [cannabinoid receptor 1] and CBR2 [cannabinoid receptor 2] expression in association with breast Show More
Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34590788/
The effectiveness of palbociclib and endocrine therapy in the treatment of HR-positive, HER2-negative mBC in the real-world setting is similar to the efficacy reported in the PALOMA-2 trial. Patients with...
Myocardial dysfunction caused by abemaciclib: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34567946/
A 68-year-old female patient with metastatic breast cancer presented 12 weeks after starting chemotherapy with abemaciclib and fulvestrant with breathlessness, peripheral edema, and weight gain. Brain natriuretic peptide (BNP) and...
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34575612/
Molecular factors that drive metastasis in premenopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), early breast cancer (EBC) are largely unknown. To identify...
Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34532471/
EVE combined with endocrine therapy is an effective treatment option for Chinese patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) breast cancer, although EVE + FUL was not...
Conclusions: EVE combined with endocrine therapy is an effective treatment option for Chinese patients with hormone-receptor-positive (HR ), human epidermal growth factor receptor-2-negative (HER2-) breast cancer, although EVE FUL was not superior to EVE AI. Liver metastasis and brain metastasis were independent risk factors for successful...